Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
09/2014
09/18/2014WO2014145408A1 Clinical methods for determining hiv-1 receptor tropism and cellular reservoirs of hiv-1 replication
09/18/2014WO2014145290A1 Attenuated influenza viruses and vaccines
09/18/2014WO2014145174A1 Immunogenic human rhinovirus (hrv) compositions
09/18/2014WO2014145095A1 Macrocyclic and bicyclic inhibitors of hepatitis c virus
09/18/2014WO2014145037A1 Methods and compositions for enhancing oxygen levels in tissues
09/18/2014WO2014144850A1 Methods of treating cancer and preventing cancer drug resistance
09/18/2014WO2014144710A1 Methods and compositions for bacteria infections
09/18/2014WO2014144295A1 Ceftolozane antibiotic compositions
09/18/2014WO2014144097A1 Antifungal drugs
09/18/2014WO2014144087A1 Sovaprevir polymorphs and methods of manufacture thereof
09/18/2014WO2014144024A1 Hyr1 compositions and methods for treating fungal and bacterial pathogens
09/18/2014WO2014144004A1 Peptides with antifungal activity and methods of using the peptides
09/18/2014WO2014143992A1 Treating lysosomal storage disease
09/18/2014WO2014143907A1 Novel dosing regimens of celgosivir for the treatment of dengue
09/18/2014WO2014143781A1 Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities
09/18/2014WO2014143768A1 Tricyclic heterocycles as bet protein inhibitors
09/18/2014WO2014143643A1 Acyclic nucleoside phosphonate diesters
09/18/2014WO2014142915A1 Methods for producing a biodegradable chitosan composition and uses thereof
09/18/2014WO2014142757A1 Hybrid nanomaterial of graphene oxide nanomaterial and cationic quaternized chitosan
09/18/2014WO2014142705A1 A cytokine-containing drug having an antiviral, antimicrobial, immunomodulatory and anti-inflammatory effect for treating and prophylaxis of infectious diseases
09/18/2014WO2014142645A1 Antiviral activity of quercetin against japanese encephalitis virus
09/18/2014WO2014142644A1 Antiviral activity of baicalein against japanese encephalitis virus
09/18/2014WO2014142298A1 Novel hydroxamic acid derivative or salt thereof
09/18/2014WO2014142117A1 Anti-staphylococcus antibody, method for manufacturing same, and usage of same
09/18/2014WO2014141218A1 Novel 1, 2, 4-oxadiazol compounds active against gram-positive pathogens
09/18/2014WO2014141177A1 New arylaminoalcohol derivatives with antiplasmodial activity
09/18/2014WO2014141132A1 NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
09/18/2014WO2014140695A1 Solid oral formulation of a pyrrolidine substituted flavone compound
09/18/2014WO2014140680A1 Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
09/18/2014WO2014140671A1 New arylaminoalcohol derivatives with antiplasmodial activity
09/18/2014WO2014140597A1 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
09/18/2014WO2014140582A1 Kinase inhibitors
09/18/2014WO2014140558A1 Method for identifying a bacterial infection
09/18/2014WO2014140391A1 Use of garvicin a as an antimicrobial product
09/18/2014WO2014140365A1 Microbicidally active imidazopyridine derivatives
09/18/2014WO2014140080A1 Lactobacillus plantarum ncc 2936 preparations and oral health
09/18/2014WO2014140075A1 Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
09/18/2014WO2014140072A1 Etoposide and prodrugs thereof for use in targeting cancer stem cells
09/18/2014WO2014139512A1 Derivatives of indoles and carbazoles, method for the production thereof and use thereof as mrsa-sensitive antibiotics
09/18/2014WO2014139476A1 Epitope of rsv fusion protein and antibody identifying same
09/18/2014WO2014139468A1 Fusion protein molecules and method of use
09/18/2014WO2014139359A1 Hepatitis b vaccine
09/18/2014WO2014139329A1 Spray-dried powder comprising vancomycin hydrochloride, and industrial manufacturing method thereof
09/18/2014WO2014139033A1 Compounds and compositions for drug release
09/18/2014WO2014138927A1 Treatment of gluten intolerance and related conditions
09/18/2014WO2014138924A1 Compositions and methods for treating clostridium difficile-associated diseases
09/18/2014WO2014138833A1 Compounds, use, pharmaceutical composition for inhibiting reductase in microorganisms, inha binder and method for obtaining inha binders
09/18/2014WO2014138823A1 Compounds and uses thereof in the treatment/prevention of gram-negative bacterial infections
09/18/2014WO2013164337A9 Pyrimidine derivatives for the treatment of bacterial diseases
09/18/2014WO2013091089A9 Three-dimensional cavities of dendritic cell immunoreceptor (dcir), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (hiv-1)
09/18/2014US20140271921 Pharmaceutical composition
09/18/2014US20140271637 Methods of administering anti-tnfalpha antibodies
09/17/2014EP2778166A1 Thioxanthene derivatives for the treatment of infectious diseases
09/17/2014EP2778159A1 7-{(3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
09/17/2014EP2777705A1 Ceftolozane antibiotic compositions
09/17/2014EP2776567A2 Compositions and methods for treatment of cytomegalovirus
09/17/2014EP2776559A1 Novel bacteriophages
09/17/2014EP2776471A1 Stable peptide-based furin inhibitors
09/17/2014EP2776463A1 Neutralizing gp41 antibodies and their use
09/17/2014EP2776445A1 Therapeutically active thiazolo-pyrimidine derivatives
09/17/2014EP2776439A1 Purine derivatives for the treatment of viral infections
09/17/2014EP2776438A1 Substituted purine nucleosides, phosphoramidate and phosphordiamidate derivatives for treatment of viral infections
09/17/2014EP2776416A1 Pharmaceutical compounds
09/17/2014EP2776410A1 Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
09/17/2014EP2776396A2 Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
09/17/2014EP2776394A1 (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
09/17/2014EP2776393A1 Nampt inhibitors
09/17/2014EP2776069A1 Carrier molecule comprising a spr0096 and a spr2021 antigen
09/17/2014EP2776063A1 Influenza virus -like particles (vlps) comprising hemagglutinin produced nicotiana tabacum
09/17/2014EP2776024A1 Methods and compositions for treating hepatitis c virus
09/16/2014US8835500 Pharmaceutical formulations of amyloid inhibiting compounds
09/16/2014US8835382 Lipopeptide compositions and related methods
09/16/2014US8834930 Pulmonary delivery of a fluoroquinolone
09/16/2014US8834900 Combination motif immune stimulatory oligonucleotides with improved activity
09/15/2014CA2809714A1 Infectious genomic dna clone and serological profile of torque teno sus virus 1 and 2
09/12/2014WO2014138425A1 Cyclosporine a-steroid conjugates
09/12/2014WO2014138403A1 Antibiotic conjugates
09/12/2014WO2014138375A1 Antibiotic conjugates linked with steroid drugs
09/12/2014WO2014138374A1 Oral combination therapy for treating hcv infection in specific patient sub-population
09/12/2014WO2014138359A1 Steroid antibiotic conjugates
09/12/2014WO2014138350A1 Antibiotic conjugates directly linked with steroid drugs
09/12/2014WO2014138343A1 Antibiotic conjugates with nonsteroidal anti-inflammatory drugs
09/12/2014WO2014138302A1 Quinazolinone antibiotics
09/12/2014WO2014138239A1 Compounds for the treatment of hepatitis c
09/12/2014WO2014138199A1 Pyrimidine compounds for the treatment of hepatitis c
09/12/2014WO2014137930A1 Thiophosphate nucleosides for the treatment of hcv
09/12/2014WO2014137929A1 Methods for treating hepatitis c virus
09/12/2014WO2014137926A1 3'-deoxy nucleosides for the treatment of hcv
09/12/2014WO2014137869A1 Hepatitis c virus inhibitors
09/12/2014WO2014137301A1 Hydrazones and thiazolidinones derived from diflunisal
09/12/2014WO2014137248A1 Method for producing antirabies vaccine
09/12/2014WO2014136931A1 Infection protection agent
09/12/2014WO2014136845A1 Method for producing mature dendritic cell population
09/12/2014WO2014136282A1 Crystalline form having specific crystal habit and pharmaceutical composition|containing this crystalline form as active ingredient
09/12/2014WO2014135638A1 Piroxicam for use in the prophylactic and therapeutic treatment of cmv infections
09/12/2014WO2014135483A1 Antiviral compounds
09/12/2014WO2014135472A1 Antiviral compounds
09/12/2014WO2014135471A1 Antiviral compounds
09/12/2014WO2014135423A1 N-heteroaryl substituted aniline derivatives as hcv-antivirals
09/12/2014WO2014135123A1 17α-ethynyl-androst-5-ene-3β,7β,17β-triol ophthalmic preparation
1 ... 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 ... 1798